171 results
8-K
EX-10.1
br9rl1pahy6
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
S-8
EX-23.1
lp2teqf 12wzvyo
30 Nov 23
Registration of securities for employees
4:16pm
8-K
ku1v27xs
14 Nov 23
Other Events
12:00am
8-K
EX-23.1
8i6u5kvy 0m9
14 Nov 23
Other Events
12:00am
8-K
EX-99.1
h1szzendh y4dc0fm
8 Nov 23
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:37am
8-K
EX-99.1
yv4783j jj4uf
31 Oct 23
Adaptimmune Reports Positive Data with Lete-cel1 from an Interim Analysis of the Pivotal IGNYTE-ESO Trial for People with Synovial Sarcoma or MRCLS
8:07am
8-K/A
jlt17x6hrq7j
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K/A
EX-23.1
v6ixuu vx6sex
10 Aug 23
Financial Statements and Exhibits
4:05pm
8-K
EX-99.1
9vxo iv7x7
9 Aug 23
Adaptimmune Reports Second Quarter Financial Results and Business Update
7:42am
8-K
EX-10.2
jhe9r
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
00s0rjqhek e1
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.3
h13cg3mew7v bhj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
6urtmo t0z0c
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm